About FDA
Percentage of administrative ANADAs (ANADAs submitted after all scientific decisions have been made in the JINAD process) completed on time
Dictionary: A generic new animal drug is a copy of an approved new animal drug for which patents or other periods of exclusivity are near expiration. In order for a generic animal drug to be marketed in the United States, it must be the subject of an approved ANADA. Administrative ANADAs are submitted after all scientific decisions have been made in the JINAD process.
Note: October 1, 2008 is the effective date of the AGDUFA.
Information is current as of February 28, 2013.
Fiscal Year - 2011
| Time | Target | Percent |
|---|---|---|
| Oct 2010 | 90 | - |
| Nov 2010 | 90 | - |
| Dec 2010 | 90 | - |
| Jan 2011 | 90 | - |
| Feb 2011 | 90 | - |
| Mar 2011 | 90 | - |
| Apr 2011 | 90 | - |
| May 2011 | 90 | - |
| Jun 2011 | 90 | - |
| Jul 2011 | 90 | - |
| Aug 2011 | 90 | - |
| Sep 2011 | 90 | - |
Footnotes
- This metric is also an Animal Generic Drug User Fee Program performance goal. In the yearly performance report to Congress, performance is reported for a defined fiscal year receipt cohort. The methodology for reporting by fiscal year receipt cohort calculates performance statistics for submissions for the fiscal year FDA received them, regardless of when FDA ultimately acted on or approved the submissions. The data reported here is the measurement of the number of applications reviewed in a given month regardless of the cohort year.
Glossary
JINAD
Generic Investigational New Animal Drug
AGDUFA
Animal Generic Drug User Fee Act
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.







